Dingdang Health Technology Group Ltd. (Dingdang Health) has disclosed a repurchase of 634,000 ordinary shares on 23 October 2026, according to its Next Day Disclosure Return filed with the Hong Kong Stock Exchange.
The on-market buyback was executed within a price band of HK$0.85 to HK$0.875 per share, producing a volume-weighted average repurchase price of HK$0.8661. Aggregate consideration totalled HK$0.55 million, and all repurchased shares were retained as treasury stock.
Post-transaction, Dingdang Health’s issued share capital (excluding treasury shares) declined by 0.05 % to 1.22486 billion shares. Treasury shares increased to 15.46 million, representing 1.25 % of the company’s 1.24 billion total issued shares. No repurchased shares have been cancelled to date.
The purchase formed part of the repurchase mandate approved by shareholders on 23 June 2026, which authorises the company to buy back up to 124.32 million shares. Including the latest trade, Dingdang Health has repurchased 18.32 million shares under this mandate—about 1.47 % of the shares outstanding on the mandate date—leaving capacity for a further 106.00 million shares.
In accordance with Hong Kong listing rules, Dingdang Health is subject to a moratorium on issuing new shares or disposing of treasury shares until 22 November 2026.
Comments